Company development · November 18, 2026 · Merck (MRK)

Merck Discontinues Nemtabrutinib’s BELLWAVE Development Program

Reported decision

In its November 17 announcement, Merck said it is discontinuing the clinical development program for nemtabrutinib, an investigational blood-cancer treatment.

The company said an external data monitoring committee’s review of Phase 3 BELLWAVE-011 suggested that benefits might not outweigh risks in that study. Merck said its subsequent review confirmed that assessment and led to discontinuing the broader program, including Phase 3 BELLWAVE-008 and BELLWAVE-010.

Merck said analyses remain ongoing and results will be shared with the scientific community. It is informing investigators and advises trial participants to discuss next steps with their study team and physician.

Analysis: a pipeline decision with unanswered details

Our interpretation is that this removes a development pathway from Merck’s pipeline. The decision concerns an investigational program; it should not be described as a recall of an approved medicine.

The announcement does not quantify a resulting earnings change or provide the completed trial analyses. Readers should distinguish the company’s decision and stated rationale from conclusions that would require detailed clinical results or later financial disclosures. No revenue replacement estimate, share-price forecast or trading recommendation is offered.

Continue reading

Browse other company developments in the market-report index or return to the clock dashboard.